, Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL, Journal of Magnetic Resonance Imaging, vol.180, issue.5, pp.1206-1212, 2014.
DOI : 10.1016/j.juro.2008.07.051
, Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities - a radiologist's perspective, NMR in Biomedicine, vol.155, issue.3, pp.3-15, 2014.
DOI : 10.1016/S0022-5347(01)66366-3
, The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer, Acta Radiologica, vol.82, issue.1, pp.107-114, 2016.
DOI : 10.1016/j.ejrad.2013.02.021
, The Impact of Multiparametric Pelvic Magnetic Resonance Imaging on Risk Stratification in Patients With Localized Prostate Cancer, Urology, vol.84, issue.1, pp.132-137, 2014.
DOI : 10.1016/j.urology.2014.03.012
, Functional MR Imaging of Prostate Cancer, RadioGraphics, vol.27, issue.1, pp.63-75, 2007.
DOI : 10.1148/rg.271065078
, Prostate Cancer: Multiparametric MR Imaging for Detection, Localization, and Staging, Radiology, vol.261, issue.1, pp.46-66, 2011.
DOI : 10.1148/radiol.11091822
, Pitfalls in Interpreting mp-MRI of the Prostate: A Pictorial Review with Pathologic Correlation, Insights into Imaging, vol.24, issue.5, pp.611-630, 2015.
DOI : 10.1148/rg.245045017
, Assessment of Biologic Aggressiveness of Prostate Cancer: Correlation of MR Signal Intensity with Gleason Grade after Radical Prostatectomy, Radiology, vol.246, issue.1, pp.168-176, 2008.
DOI : 10.1148/radiol.2461070057
, PI-RADS Prostate Imaging ??? Reporting and Data System: 2015, Version 2, European Urology, vol.69, issue.1, pp.16-40207, 2013.
DOI : 10.1016/j.eururo.2015.08.052
,
, Comparison of interreader reproducibility of the prostate imaging reporting and data system and likert scales for evaluation of multiparametric prostate MRI, AJR Am J Roentgenol, vol.201, pp.612-618, 2013.
,
, Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination, Magn Reson Imaging, vol.27, pp.497-502, 2009.
, Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia, Urology, vol.60, issue.3, pp.434-441, 2002.
DOI : 10.1016/S0090-4295(02)01905-2
, Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial, The Lancet, vol.379, issue.9821, pp.1103-1111, 2012.
DOI : 10.1016/S0140-6736(11)61619-X
, MAPPED study design: A 6- month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging Prostate cancer: diagnosis and management NICE guidelines, UK. Available via https, Contemp Clin Trials National Institute for Health and Clinical Excellence Eur Radiol, vol.3422, issue.16, pp.80-89746, 2012.
, NMR properties of human median nerve at 3 T: Proton density, T1, T2, and magnetization transfer, Journal of Magnetic Resonance Imaging, vol.24, issue.4, pp.982-986, 2009.
DOI : 10.2214/ajr.183.2.1830343
, Osmotic effects on theT2 relaxation decay of in vivo muscle, Magnetic Resonance in Medicine, vol.81, issue.3, pp.592-599, 2001.
DOI : 10.1097/00000542-199411000-00024
, The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED???A Randomized, Placebo Controlled, Double-Blind Clinical Trial, The Journal of Urology, vol.197, issue.4, pp.1006-1013, 2017.
DOI : 10.1016/j.juro.2016.11.090
URL : https://hal.archives-ouvertes.fr/hal-01518408
, MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial, European Radiology, vol.56, issue.11, 2017.
DOI : 10.1016/j.eururo.2008.11.051
URL : https://hal.archives-ouvertes.fr/hal-01624586
, mapping of the prostate using three-dimensional dual echo steady state MRI at 3T, Magnetic Resonance in Medicine, vol.42, issue.6, pp.1720-1729, 2016.
DOI : 10.1002/jmri.24870
, relaxation during radiotherapy for prostate cancer, Journal of Magnetic Resonance Imaging, vol.5, issue.4, pp.909-916, 2013.
DOI : 10.1016/0730-725X(87)90480-2
, Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer, Radiology, vol.283, issue.3, pp.729-738, 2017.
DOI : 10.1148/radiol.2017161599
, Motion corrected DWI with integrated T2-mapping for simultaneous estimation of ADC, T2-relaxation and perfusion in prostate cancer, Magnetic Resonance Imaging, vol.39, pp.162-167, 2017.
DOI : 10.1016/j.mri.2017.03.003
, Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T2-mapping MRI sequence, Magnetic Resonance Imaging, vol.33, issue.5, pp.525-530, 2015.
DOI : 10.1016/j.mri.2015.02.006
, mapping of the prostate using three-dimensional dual echo steady state MRI at 3T, Magnetic Resonance in Medicine, vol.42, issue.6, pp.1720-1729, 2016.
DOI : 10.1002/jmri.24870
,
, Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume, Br J Radiol, vol.86, p.20120469, 1024.
, Improved multiparametric MRI discrimination between low?risk prostate cancer and benign tissues in a small cohort of 5??reductase inhibitor treated individuals as compared with an untreated cohort Role of multiparametric 3.0 Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance Reporting Magnetic Resonance Imaging in men on active surveillance for prostate cancer: the PRECISE recommendations ? A report of a European School of Oncology Task Force, 864?870. 31. Moore CM, pp.3696-30648, 2014.
, Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate Cancer, The Journal of Urology, vol.189, issue.3, pp.860-866
DOI : 10.1016/j.juro.2012.10.009